文献速递产科母胎医学

一步法或两步法筛查妊娠期糖尿病:孰优孰劣?

One-step or 2-step testing for gestational diabetes: which is better?
PubMed 文献 · Am J Obstet Gynecol · 2021-05-21

本文比较美国妇产科医师学会推荐的两步法与国际糖尿病与妊娠研究组推荐的一步法筛查妊娠期糖尿病。一步法诊断率18%~20%,是两步法的2~3倍,但一项随机对照试验认为两种方法对短期不良妊娠结局影响无显著差异。作者对该试验的结论提出质疑,认为其样本量假设、随机交叉和治疗污染等因素可能掩盖了一步法的获益。

要点

  • 一步法需空腹但仅单次升高即可诊断,诊断率18%~20%,为两步法2~3倍。
  • 两步法无需空腹,约15%~20%筛查女性需行100g 3小时口服葡萄糖耐量试验。
  • 作者认为近期RCT不足以否定一步法,其样本量假设和方案执行存在局限。

核心结论

  • 作者认为近期随机对照试验的结论不足以证明一步法无优势,其设计局限可能掩盖了一步法对人群健康的潜在获益。

研究设计与样本

  • 本文为针对一项随机对照试验及其述评的评论性文章,未报告该试验的具体样本量。

主要发现

  • 一步法诊断妊娠期糖尿病的比例为18%~20%,是两步法的2~3倍,但低于美国育龄女性糖尿病前期24%的比例。
  • 两步法约15%~20%的筛查女性需行100g 3小时口服葡萄糖耐量试验。
  • 随机对照试验中,27%随机至一步法的女性实际接受了两步法检测,6%的研究队列未接受任何检测。

关键数值与推荐

  • 两步法:24~28周行50g 1小时葡萄糖挑战试验,超过阈值后行100g 3小时口服葡萄糖耐量试验,2项及以上升高值诊断妊娠期糖尿病。
  • 一步法:行75g 2小时口服葡萄糖耐量试验,1项及以上升高值诊断妊娠期糖尿病,需空腹。

临床怎么用

  • 临床选择筛查方案时需权衡诊断率、便利性(是否空腹、就诊次数)及资源投入。
  • 解读一步法与两步法比较的研究时,需关注随机交叉、治疗污染和样本量假设对结果的影响。

局限性

  • 本文为评论性文章,未提供原始研究数据。
  • 所评论的随机对照试验未考虑母婴长期获益,且样本量基于20%不良结局改善的假设,作者认为该假设不现实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the United States, the common approach to detecting gestational diabetes mellitus is the 2-step protocol recommended by the American College of Obstetricians and Gynecologists. A 50 g, 1-hour glucose challenge at 24 to 28 weeks' gestation is followed by a 100 g, 3-hour oral glucose tolerance test when a screening test threshold is exceeded. Notably, 2 or more elevated values diagnose gestational diabetes mellitus. The 2-step screening test is administered without regard to the time of the last meal, providing convenience by eliminating the requirement for fasting. However, depending upon the cutoff used and population risk factors, approximately 15% to 20% of screened women require the 100 g, 3-hour oral glucose tolerance test. The International Association of Diabetes and Pregnancy Study Groups recommends a protocol of no screening test but rather a diagnostic 75 g, 2-hour oral glucose tolerance test. One or more values above threshold diagnose gestational diabetes mellitus. The 1-step approach requires that women be fasting for the test but does not require a second visit and lasts 2 hours rather than 3. Primarily because of needing only a single elevated value, the 1-step approach identifies 18% to 20% of pregnant women as having gestational diabetes mellitus, 2 to 3 times the rate with the 2-step procedure, but lower than the current United States prediabetes rate of 24% in reproductive aged women. The resources needed for the increase in gestational diabetes mellitus are parallel to the resources needed for the increased prediabetes and diabetes in the nonpregnant population. A recent randomized controlled trial sought to assess the relative population benefits of the above 2 approaches to gestational diabetes mellitus screening and diagnosis. The investigators concluded that there was no significant difference between the 2-step screening protocol and 1-step diagnostic testing protocol in their impact on population adverse short-term pregnancy outcomes. An accompanying editorial concluded that perinatal benefits of the 1-step approach to diagnosing gestational diabetes mellitus "appear to be insufficient to justify the associated patient and healthcare costs of broadening the diagnosis." We raise several concerns about this conclusion. The investigators posited that a 20% improvement in adverse outcomes among the entire pregnancy cohort would be necessary to demonstrate an advantage to the 1-step approach and estimated the sample size based on that presumption, which we believe to be unlikely given the number of cases that would be identified. In addition, 27% of the women randomized to the 1-step protocol underwent 2-step testing; 6% of the study cohort had no testing at all. A subset of women assigned to 2-step testing did not meet the criteria for gestational diabetes mellitus but were treated as such because of elevated fasting plasma glucose levels, presumably contributing to the reduction in adverse outcomes but not to the number of gestational diabetes mellitus identified, increasing the apparent efficacy of the 2-step approach. No consideration was given to long-term benefits for mothers and offspring. All these factors may have contributed to obscuring the benefits of 1-step testing; most importantly, the study was not powered to identify what we understand to be the likely impact of 1-step testing on population health.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Coustan DR, Dyer AR, Metzger BE, et al. One-step or 2-step testing for gestational diabetes: which is better? Am J Obstet Gynecol. 2021. PMID: 34023312. doi:10.1016/j.ajog.2021.05.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。